Key Insights

Highlights

Success Rate

66% trial completion

Published Results

15 trials with published results (12%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

14.7%

19 terminated out of 129 trials

Success Rate

66.1%

-20.4% vs benchmark

Late-Stage Pipeline

9%

11 trials in Phase 3/4

Results Transparency

41%

15 of 37 completed with results

Key Signals

15 with results66% success19 terminated

Data Visualizations

Phase Distribution

110Total
Not Applicable (50)
Early P 1 (4)
P 1 (14)
P 2 (31)
P 3 (10)
P 4 (1)

Trial Status

Completed37
Recruiting36
Active Not Recruiting28
Terminated19
Not Yet Recruiting5
Withdrawn3

Trial Success Rate

66.1%

Benchmark: 86.5%

Based on 37 completed trials

Clinical Trials (129)

Showing 20 of 20 trials
NCT06058377Phase 3RecruitingPrimary

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT06763328Phase 3Recruiting

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

NCT07391774Phase 3RecruitingPrimary

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

NCT04816006Not ApplicableRecruiting

Breast Cancer, Reasoning, and Activity Intervention

NCT06392789Not ApplicableCompleted

A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors

NCT03939481Active Not Recruiting

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

NCT05874297Not ApplicableNot Yet Recruiting

Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer

NCT05812807Phase 3RecruitingPrimary

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

NCT06876714Phase 3Recruiting

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

NCT05183828Phase 4Terminated

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

NCT06388122Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

NCT07474090Not ApplicableActive Not Recruiting

Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial

NCT05786664Recruiting

Breast Cancer Survivorship Biorepository

NCT07259304Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

NCT06401889Recruiting

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

NCT04329065Phase 2Recruiting

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

NCT07594678Phase 2Not Yet Recruiting

Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients

NCT05368428Not ApplicableTerminated

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

NCT04001829Phase 2Active Not Recruiting

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

NCT05379153Phase 3Recruiting

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

Scroll to load more

Research Network

Activity Timeline